The China Spinal Cord Injury Network (ChinaSCINet) recently conducted phase-two clinical trials in Hong Kong and Kunming, where umbilical cord blood cells were transplanted together with lithium into people with chronic complete spinal cord injury.
The results of these trials are being prepared for publication soon, says ChinaSCINet CEO Wise Young. “Based on these results, we are now planning to initiate phase III clinical trials in China, India, Norway and the USA.”
ChinaSCINet plans to test 120 subjects with chronic complete spinal cord injury and to test different combinations of therapies. All patients would undergo three to six months of intensive locomotor training and be assessed for two years.